Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Glaukos (GKOS) stock in plain English

Free brief · no signupStart here
GKOSPublished Nov 17, 2026
Glaukos Corp
Healthcare · Medical Devices
Manufactures microscopic surgical stents that drain intraocular fluid to treat glaucoma.
Assets:
Aliso Viejo headquartersCentralizes device research and corporate leadership in California
iStent product lineMicroscopic surgical implants designed for trabecular bypass procedures
Burlington facilityProduces photochemical solutions for therapeutic corneal cross-linking
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

67
OPS ScoreOperating finances
Latest quote
+2.15%$238.10
$14.09B
n/a (loss)
$690.24M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 17, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was GKOS. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Glaukos (GKOS) do?

Glaukos Corp (GKOS) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures microscopic surgical stents that drain intraocular fluid to treat glaucoma. Builds microscopic surgical stents and slow-release intraocular implants to reduce fluid pressure inside the eye. It is worth $14.09B on the market and sold $690.24M over the last year.

Market cap
$14.09B
P/E ratio
None (reported a loss)
Annual sales
$690.24M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 17, 2026

Brands and businesses behind GKOS

  • iStent: Microscopic titanium implants sold to ophthalmic surgeons to reduce internal fluid pressure in patients with glaucoma.
  • Photrexa: Prescription riboflavin eye drop formulations sold to treat progressive corneal thinning through photo-activation therapy.
  • iDose TR: An implantable drug delivery device that continuously releases travoprost directly into the anterior chamber of the eye.

GKOS’s flags, in plain English

Each flag is a number from Glaukos’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.

Stupid Cash

Can pay this year's bills 4.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 81.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Low debt

Low debt, only 14% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -24.6%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

1 more green flag open with the free trial. Try it free for 7 days.

Questions about GKOS

How big is Glaukos?

Glaukos’ market cap is $14.09B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $690.24M: what customers paid the company over the last year, before any costs.

What is GKOS’s P/E ratio?

GKOS has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with GKOS?

The business relies heavily on Medicare fee schedules and reimbursement coding for eye stent procedures. That is one risk on Glaukos’ card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Glaukos’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GKOS’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card